Patient clinicodemographic characteristics
JEB, non‐Hodgkin lymphoma, chickenpox, hydrocele, thalassemia, tetanus
ALLERGY, CHICKENPOX, DISEASE, NEPHROTIC SYNDROME, THALASSEMIA, TETANUS, DISEASES
This study enrolled 166 participants, of whom two did not meet the inclusion criteria, and four did not complete the study. Eventually, 160 participants who completed the study treatment were included in the FAS and SS analyses (Figure Study flowchart.The baseline characteristics of the included participants are shown in Table Baseline characteristics of the patients.Abbreviations: CAV/CE, cyclophosphamide + epirubicin + vincristine/ etoposide+ carboplatin; CAV/IE, cyclophosphamide + epirubicin + vincristine/ifosfamide + etoposide; CAV/VIP, cyclophosphamide + epirubicin + vincristine/ifosfamide + etoposide + cisplatin; JEB, etoposide + carboplatin + bleomycin; SCCCG‐BL, a modified BFM protocol for non‐Hodgkin lymphoma; VAC/VII, cyclophosphamide + actinomycin‐D + vincristine/ifosfamide + irinotecan (detailed chemotherapy regimens are available in supplementary materials).Underlying diseases or comorbidities included thalassemia, hydrocele, nephrotic syndrome, chickenpox, and FAVA disease.Allergy drugs included doxorubicin hydrochloride liposome injection, cephalosporin, amikacin, tetanus antitoxin, diphenhydramine, and albendazole.